tbuckley/cabot-search huggingface dataset:
The effect of fish oil on chemotherapy activity in mice: Clinical implications.
Authors: L. G. Daenen, J. M. L. Roodhart, E. C. Stigter, M. G. Gerritsen, R. H. Medema, A. B. Brenkman, E. E. Voest
Journal: Journal of Clinical Oncology (2011)

10532 Background: Environment-mediated resistance to chemotherapy is emerging as a cause of treatment failure. In mouse models, we showed that mesenchymal stem cells (MSCs) are activated by platinum-based chemotherapy to secrete two unique platinum-induced fatty acids (PIFAs): KHT(n-6) and 16:4(n-3) which induce resistance to a broad spectrum of chemotherapies. These fatty acids are also present in various food products and supplements. Fish oil and some algae are frequently used by cancer patients because of their perceived positive health effects. Therefore, we hypothesized that the use of fish oil and specific algae containing PIFAs may have an adverse effect on the anti-tumor effects of chemotherapy. Methods: Two different mouse tumor models were established in which we investigated whether co-administration of orally administered PIFAs, fish oil products and algae extracts influenced the response to chemotherapy. Results: We found that our identified PIFAs are abundantly present in commercially available fish oil products (0.4-0.6uM 16:4(n-3)) and algae extracts (27uM 16:4(n-3)). First we tested whether the purified PIFAs induced resistance when administered orally. We found that orally administered, pure PIFAs induced resistance to cisplatin in both our tumor models; mean tumor volume after cisplatin 71 mm3 (SEM 5) vs 233 mm3 (SEM 44) after cisplatin plus PIFAs. Next, we fed tumor-bearing mice two types of commercially available fish oils or algae extracts and treated them with cisplatin. A single oral dose of 100ul of two different commercially available fish oil products or algae extracts resulted in neutralization of the anti-tumor effects of cisplatin in two models; cisplatin 71 mm3 (SEM 5) vs cisplatin + fish oil 294 mm3 (SEM 49). Orally administered EPA, the main component of most fish oil products, which served as a control, had no effect on response to chemotherapy. Conclusions: Commercially available fish oil and algae extracts can induce resistance to chemotherapy at doses similar to the advised daily dose in humans. The use of these products during chemotherapy treatment should therefore be avoided. These results support the clinical relevance of these PIFAs in the development of resistance to chemotherapy.
P3-230: The role of surgical resection for Pancoast tumors after neoadjuvant chemoradiation
Authors: Ingrid Kappers, Jacobus A. Burgers, Jose S. Belderbos, Johanna W. Sandick, Nico v. Zandwijk, Houke M. Klomp
Journal: Journal of Thoracic Oncology (2007)
Skin biopsy utilization and melanoma incidence among Medicare beneficiaries
Authors: M.A. Weinstock, J.P. Lott, Q. Wang, L.J. Titus, T. Onega, H.D. Nelson, L. Pearson, M. Piepkorn, R.L. Barnhill, J.G. Elmore, A.N.A. Tosteson
Journal: British Journal of Dermatology (2016)

Melanoma incidence has increased in recent decades in the U.S.A. Uncertainty remains regarding how much of this increase is attributable to greater melanoma screening activities, potential detection bias and overdiagnosis. To use a cross-sectional ecological analysis to evaluate the relationship between skin biopsy and melanoma incidence rates over a more recent time period than prior reports. Examination of the association of biopsy rates and melanoma incidence (invasive and in situ) in SEER-Medicare data (including 10 states) for 2002-2009. The skin biopsy rate increased by approximately 50% (6% per year) throughout this 8-year period, from 7012 biopsies per 100 000 persons in 2002 to 10 528 biopsies per 100 000 persons in 2009. The overall melanoma incidence rate increased approximately 4% (< 1% per year) over the same time period. The incidence of melanoma in situ increased approximately 10% (1% per year), while the incidence of invasive melanoma increased from 2002 to 2005 then decreased from 2006 to 2009. Regression models estimated that, on average, for every 1000 skin biopsies performed, an additional 5·2 (95% confidence interval 4·1-6·3) cases of melanoma in situ were diagnosed and 8·1 (95% confidence interval 6·7-9·5) cases of invasive melanoma were diagnosed. When considering individual states, some demonstrated a positive association between biopsy rate and invasive melanoma incidence, others an inverse association, and still others a more complex pattern. Increased skin biopsies over time are associated with increased diagnosis of in situ melanoma, but the association with invasive melanoma is more complex.
Case 16-1962
Authors: Richard Chute
Journal: New England Journal of Medicine (1962)

Presentation of CaseA twenty-five-year-old woman entered the hospital because of pain in the left flank.The patient was well until seven weeks before admission, when a "kidney infection" developed after a normal pregnancy and delivery. She complained of aching pain, which was localized to the left flank and exacerbated by lying down. The temperature rose once or twice daily, usually in association with chills. She did not respond to tetracycline, nitrofurantoin (Furadantin) and sulfisoxazole (Gantrisin), and intravenous pyelograms showed a cyst of the left kidney. She had a chronic, dry cough, without hemoptysis, for two months before admission and . . .
Abstract 3582: A Risk Score to Predict In-hospital Mortality Following Primary Angioplasty from New York State Reporting System
Authors: Kartik Mani, Oussama Dagher, Seth Sokol, Abdissa Negassa, Carlos Vela, E.Scott Monrad, V.S Srinivas
Journal: Circulation (2007)

Background: Although several risk scores exist that risk-stratify patients during elective percutaneous coronary intervention (PCI), few have been developed in primary angioplasty setting. Therefor...
Thymidylate synthase (TS) gene expression in patients with ALK positive (+) non-small cell lung cancer (NSCLC): Implications for therapy.
Authors: David R. Gandara, Eric Huang, Sonal Desai, Philip C. Mack, Laurel Beckett, Craig Stephens, Gary Zeger, Kathleen D. Danenberg, Martin Karl Herbert Maus, Tianhong Li
Journal: Journal of Clinical Oncology (2012)

7582 Background: ALK+ NSCLC represents a molecular target-defined patient population highly responsive to the ALK inhibitor crizotinib. Previous reports have also suggested increased sensitivity of ALK+ NSCLC to the chemotherapeutic agent pemetrexed. Thymidylate synthase (TS) is a candidate predictive biomarker for pemetrexed activity. Here we report analysis of the Response Genetics Inc. (RGI) database for this association and implications for therapy. Methods: ALK fusion was identified by a novel RT-PCR assay (Danenberg et al: ASCO 2010). For TS, RNA from microdissected formalin-fixed paraffin-embedded tumors was analyzed as previously described, reported as the ratio of gene expression to β-actin. For reference, a TS level &lt;2.33 is the cutpoint for sensitivity. Results: TS levels were available from 63 ALK+ patients and 1,698 ALK- control lung adenocarcinoma patients. All ALK+ patients had adenocarcinomas without EGFR or KRAS mutations. Median age: 59.0 (range 33-88), gender (male/female) 32/31 (51%/49%). Median TS RNA level in ALK+ patients was 2.02, range (0.55-19.44), and in ALK- patients was 3.32 (0.36-53.51), p&lt;0.0001 (Mann-Whitney test). The majority of ALK+ patients (N=43, 68%) had a TS level &lt;2.33 cutpoint, compared to only 32% of ALK- patients (N=551, p&lt;0.0001). Conclusions: This analysis demonstrates relatively low TS gene expression in ALK+ patient tumors as determined by RT-PCR. These data provide a mechanism of action supportive of pemetrexed sensitivity for ALK+ NSCLC. [Table: see text]
The Balance of Open vs Endovascular Aneurysm Repair
Authors: Gilbert R. Upchurch
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Impact of the ACUITY and TIMI major bleeding definitions on one-year mortality in patients with acute coronary syndromes
Authors: Steven Manoukian, Frederick Feit, Michele D Voeltz, Ramin Ebrahimi, Martial Hamon, Derek P Chew, George D Dangas, Walter Desmet, A. M Lincoff, Jeffrey W Moses, Charles Pollack, James W Hoekstra, Spencer B King, Harvey D White, E. M Ohman, Roxana Mehran, Gregg W Stone
Journal: Circulation (2007)
P2-183: Gemcitabine weekly as a radiosensitiser for the treatment of brain metastases in patients with non-small cell lung cancer: a phase I study
Authors: Yujuan Huang, Yilong Wu, Songxi Xie, Jing-Ji Yang, Yi-Sheng Huang, Ri-Qiang Lioa
Journal: Journal of Thoracic Oncology (2007)
Recurrent Novel Regions of Uniparental Disomy and Homozygous Deletions in Mycosis Fungoides Identified Using High Resolution Single Nucleotide Polymorphism Analysis.
Authors: Azim M Mohamedali, Tracey J Mitchell, Silvia Ferreira, Barbara A Guinn, Robin M. Ireland, Sean J Whittaker, Ghulam J Mufti
Journal: Blood (2009)
P2-247: The effects of NSCLC neoadjuvant therapy on the serum and tumor levels of growth factors, apoptosis and invasiveness markers
Authors: Joanna Chorostowska-Wynimko, J Zaleska, M Chabowski, A Rozy, J Zych, P Rudzinski, R Langfort, T Orlowski, K Roszkowski
Journal: Journal of Thoracic Oncology (2007)
P3-185: Predicting the risk of symptomatic radiation pneumonitis by clinical, dosimetric and biologic parameter in lung cancer patients
Authors: Yeonsil Kim, Jiyoon Kim, Young-Kyoun Kim, Hyun-Jin Park, Suk-Chan Kim, Young-Pil Wang, Jin-Hyung Kang, Ie-Ryung Yoo, Kyu-Young Lee
Journal: Journal of Thoracic Oncology (2007)
Coronary arteritis in mice after systemic injection of bacterial cell wall peptidoglycan.
Authors: Hisashi Ohkuni, Yuko Todome, Kozo Yokomuro, Yoshitami Kimura, Masamichi Ishizaki, Yu Fukuda, Yozo Masugi, Shigeyuki Hamada
Journal: Circulation (1987)

We examined cell wall peptidoglycan (PGL) derived from group A streptococcus and other bacteria for possible induction of coronary arteritis in mouse strains. The histological finding of the main trunk of the coronary arteries of BALB/c, DBA/1J, C57BL/6 and DBA/2 mice, which were given an intravenous injection of sonicated PGL fragments of st. pyogenes at 500 μg per mouse 4 times at intervals of 1 week, showed diffuse cellular infiltration in the vascular wall as well as perivascular space. Marked hyperplasia of the endothelial cells was noted and necrosis of the medial smooth muscle of the coronary artery also was observed. The elastica stain clearly demonstrated fragmentation and degeneration of the elastic fibers. The histological change of the originating site of the aorta also noted swelling or hyperplasia of the endothelial cells and perivascular cellular infiltration. PGL fragments of st. mutans, st. sanguis and s.aureus did not cause any heart lesions. coronary arteritis induced by st. pyogenes PGL could be very useful as an experimental animal model of Kawasaki's disease.
Results of a randomized phase II study of mitoxantrone versus mitoxantrone with cetuximab in metastatic castrate-resistant prostate cancer (CRPC) previously treated with docetaxel-based chemotherapy.
Authors: M. T. Fleming, M. A. Kolodziej, S. Awasthi, T. E. Hutson, D. Martincic, G. Sonpavde, Y. Wang, K. A. Boehm, L. Asmar, T. M. Beer
Journal: Journal of Clinical Oncology (2010)

4555 Background: Cetuximab (C), a chimeric monoclonal antibody with binding affinity to the epidermal growth factor receptor (EGFR), is active against androgen-independent prostate cell (AIPC) lines. No established therapy prolongs survival in CRPC patients (pts) who have received prior docetaxel (D). Mitoxantrone (M) is often used in this setting. In other cancers, C can restore sensitivity to chemotherapy. The combination of C+M was tested in D-treated CRPC pts. Methods: Pts with metastatic CRPC with evidence of progression (PSA or imaging) after D were eligible. PCWG2 guidelines for nonmeasurable disease applied. Treatment: Arm 1 (CM) C 250 mg/m2 (except 400 mg/m2 on Day 1 Cycle 1) Days 1, 8, & 15 and M 12 mg/m2 Day1; Arm 2 (M) 12 mg/m2 Day1; all pts took oral prednisone (P) 10 mg daily. Cycles were 21-days. Arm 2 pts could crossover to Arm 1 if progression was documented prior to Cycle 7 and were analyzed as Arm 2b. Radiological assessments of disease and PSA were done every 4 cycles. Results: 115 pts were enrolled, randomly assigned 2:1, and treated n=75 Arm 1 and n=40 Arm 2. Median age (Arm 1/Arm 2) was 70/70 years (range, 48-92/52-87), ECOG 0-1-2 was 35%-59%-7%/42.5%-47.5%-10%, median baseline PSA was 93/130 ng/dL. Pts received a median of 4/7 cycles; 7 pts crossed over to Arm 1 (Arm 2b) and received a median of 6 cycles of C. Results for Arm 1/Arm 2 were: median TTP (4.9/6.6 months [mos]), median time to radiographically evident progression has not been reached, response rate (measurable disease) (0% CR, 1% PR; RR=1%/ 0% CR, 3% PR; RR=3%), median time to PSA progression (2.7/2.7 mos), PSA response rate (9%/18%), median PSA doubling time on therapy (2/1.5 mos), PFS (4/5.5 mos), median OS (11/NA mos), and responses attributable to addition of C in crossover pts (RR=0%; 28.6% SD). Grade 3-4 drug related toxicities (Arm 1/Arm 2) included: neutropenia (44%/26%), leucopenia (20%/10%), fatigue (8%/8%), anemia (7%/8%), and thrombocytopenia (7%/3%); 7/5 pts experienced decreased EF. Conclusions: The combination of treatment C+M is not recommended for further study in pts with CRPC who have received docetaxel. Supported, in part, by ImClone Systems. No significant financial relationships to disclose.
DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer
Authors: Nnennaya Kanu, Maria Antonietta Cerone, Gerald Goh, Lykourgos-Panagiotis Zalmas, Jirina Bartkova, Michelle Dietzen, Nicholas McGranahan, Rebecca Rogers, Emily K. Law, Irina Gromova, Maik Kschischo, Michael I. Walton, Olivia W. Rossanese, Jiri Bartek, Reuben S. Harris, Subramanian Venkatesan, Charles Swanton
Journal: Genome biology (2016)

The APOBEC3 family of cytidine deaminases mutate the cancer genome in a range of cancer types. Although many studies have documented the downstream effects of APOBEC3 activity through next-generation sequencing, less is known about their upstream regulation. In this study, we sought to identify a molecular basis for APOBEC3 expression and activation. HER2 amplification and PTEN loss promote DNA replication stress and APOBEC3B activity in vitro and correlate with APOBEC3 mutagenesis in vivo. HER2-enriched breast carcinomas display evidence of elevated levels of replication stress-associated DNA damage in vivo. Chemical and cytotoxic induction of replication stress, through aphidicolin, gemcitabine, camptothecin or hydroxyurea exposure, activates transcription of APOBEC3B via an ATR/Chk1-dependent pathway in vitro. APOBEC3B activation can be attenuated through repression of oncogenic signalling, small molecule inhibition of receptor tyrosine kinase signalling and alleviation of replication stress through nucleoside supplementation. These data link oncogene, loss of tumour suppressor gene and drug-induced replication stress with APOBEC3B activity, providing new insights into how cytidine deaminase-induced mutagenesis might be activated in tumourigenesis and limited therapeutically.
Passage of inhaled particles into the blood circulation in humas (Reply to W.M. Burch)
Authors: Abderrahim Nemmar, Phm Hoet, Maarten Thomeer, Benoit Nemery, B Vanquickenborne, H Vanbilloen, Luc Mortelmans, Marc Hoylaerts, Alfons Verbruggen, A Dinsdale
Journal: Circulation (2002)
“Take your polyp for a walk”: endoscopic retrieval of multiple colon polyps using a clip and line
Authors: Tomofumi Akasaka, Yoji Takeuchi, Yasushi Yamasaki, Noboru Hanaoka, Noriya Uedo, Ryu Ishihara, Hiroyashu Iishi
Journal: Endoscopy (2016)

Detecting and removing colonic polyps reduces the incidence of colorectal cancer [1]. Small polyps can be retrieved through a working channel into a suction trap or discarded, as almost all are indolent and pathological examination is not considered to be important [2] [3]. As large polyps (≥ 10 mm) may harbor invasive cancer, they should always be retrieved and sent for careful pathological examination. During retrieval by suction or grasping, polyps may drop off and roll back into the colon or block further endoscopic view, preventing the detection of other polyps. Moreover, the number of polyps retrieved by conventional methods is limited. This report describes a new retrieval method, using a clip and line, which does not require withdrawal and reinsertion of the colonoscope.
Fusing Sensor Paradigms to Acquire Chemical Information: An Integrative Role for Smart Biopolymeric Hydrogels
Authors: Eunkyoung Kim, Yi Liu, Hadar Ben‐Yoav, Thomas E. Winkler, Kun Yan, Xiaowen Shi, Jana Shen, Deanna L. Kelly, Reza Ghodssi, William E. Bentley, Gregory F. Payne
Journal: Advanced Healthcare Materials (2016)

The Information Age transformed our lives but it has had surprisingly little impact on the way chemical information (e.g., from our biological world) is acquired, analyzed and communicated. Sensor systems are poised to change this situation by providing rapid access to chemical information. This access will be enabled by technological advances from various fields: biology enables the synthesis, design and discovery of molecular recognition elements as well as the generation of cell-based signal processors; physics and chemistry are providing nano-components that facilitate the transmission and transduction of signals rich with chemical information; microfabrication is yielding sensors capable of receiving these signals through various modalities; and signal processing analysis enhances the extraction of chemical information. The authors contend that integral to the development of functional sensor systems will be materials that (i) enable the integrative and hierarchical assembly of various sensing components (for chemical recognition and signal transduction) and (ii) facilitate meaningful communication across modalities. It is suggested that stimuli-responsive self-assembling biopolymers can perform such integrative functions, and redox provides modality-spanning communication capabilities. Recent progress toward the development of electrochemical sensors to manage schizophrenia is used to illustrate the opportunities and challenges for enlisting sensors for chemical information processing.
P3-169: A prospective phase II trial of stereotactic radiotherapy for early stage lung cancer–treatment feasibility and tumor response
Authors: Pia Baumann, Jan Nyman, Morten Hoyer, Kristina Nilsson, Lars Ekberg, Jo-Åsmund Lund, Signe Friesland, Merete Paludan, Ingmar Lax, Karl-Axel Johansson, Nina Levin, Elisabeth Morhed, Giovanna Gagliardi, Berit Wennberg, Ninni Drugge, Lena Wittgren, Anders Traberg, Christer Sederholm, Rolf Lewensohn
Journal: Journal of Thoracic Oncology (2007)
Precision Medicine in Myelodysplastic Syndromes and Leukemias: Lessons from Sequential Mutations
Authors: Aziz Nazha, Mikkael A. Sekeres
Journal: Annual Review of Medicine (2016)

Precision medicine can be simply defined as the identification of personalized treatment that matches patient-specific clinical and genomic characteristics. Since the completion of the Human Genome Project in 2003, significant advances have been made in our understanding of the genetic makeup of diseases, especially cancers. The identification of somatic mutations that can drive cancer has led to the development of therapies that specifically target the abnormal proteins derived from these mutations. This has led to a paradigm shift in our treatment methodology. Although some success has been achieved in targeting some genetic abnormalities, several challenges and limitations exist when applying precision-medicine concepts in leukemia and myelodysplastic syndromes. We review the current understanding of genomics in myelodysplastic syndromes (MDS) and leukemias and the limitations of precision-medicine concepts in MDS.
Esophagus-like Bronchus in an Adult with Common Variable Immunodeficiency Disease
Authors: Jing Zhao, Rui Tian, Tao An, Jing Xu, Tingting Cui, Xuefeng Sun, Yong Chen, Mengzhao Wang, Baiqiang Cai, Jinming Gao, Rong Huang, Zuojun Xu
Journal: American Journal of Respiratory and Critical Care Medicine (2016)
Molecular and clinical determinants of survival following relapse after treatment of stage ii-iii colon cancer (cc). results of the translational study on the petacc 3-eortc 40993-sakk 60-00 trial
Authors: A Roth, D Klingbiel, P Yan, R Fiocca, M Delorenzi, R Labianca, D Cunningham, Eric Van Cutsem, F Bosman, Sabine Tejpar
Journal: Annals of Oncology (2010)
Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors
Authors: Amy L. Walz, Ariadne Ooms, Samantha Gadd, Daniela S. Gerhard, Malcolm A. Smith, Jaime M. Guidry Auvil, Daoud Meerzaman, Qing-Rong Chen, Chih Hao Hsu, Chunhua Yan, Cu Nguyen, Ying Hu, Reanne Bowlby, Denise Brooks, Yussanne Ma, Andrew J. Mungall, Richard A. Moore, Jacqueline Schein, Marco A. Marra, Vicki Huff, Jeffrey S. Dome, Yueh-Yun Chi, Charles G. Mullighan, Jing Ma, David A. Wheeler, Oliver A. Hampton, Nadereh Jafari, Nicole Ross, Julie M. Gastier-Foster, Elizabeth J. Perlman
Journal: Cancer Cell (2015)
NF-κB Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program
Authors: Ling Li, Zijun Yidan Xu-Monette, Chi Young Ok, Alexander Tzanko, Carlo Visco, Nora Gisin, Santiago Montes-Moreno, Karen Dybkær, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W. L. Choi, Joannes H.J.M. Van Krieken, Jooryung Huh, Maurilio Ponzoni, Andres J.M. Ferreri, Michael B. Møller, Ronald S. Go, Jane N. Winter, Miguel A. Piris, L. Jeffrey Medeiros, Ken H. Young
Journal: Blood (2014)